An important milestone for the DayOne Accelerator has been achieved. Over two intense days, the DayOne Selection Committee interviewed 36 startups, shortlisted from 194 applications received from more than 40 countries.
Executives from Pharma and Diagnostics, investors, IP and regulatory experts, as well as technology and knowledge leaders, came together to share their expertise and insights during these selection days.
From Hong Kong to San Francisco, founders pitched their solutions to improve and accelerate Pharma R&D. The proposals covered a wide range of areas within the healthtech space: digital biomarkers, techbio, digital clinical trials & remote monitoring, diagnostics, patient screening & stratification, protocol optimization, and others (e.g. data analytics).
After rich discussions and thoughtful evaluations, the committee has now selected the healthtech and techbio startups that will take part when the 2025 program kicks off in September.
Cecile Tardy-Srinivasan, DayOne Portfolio & Accelerator Lead, shared, “The two-day Selection Committee meeting was an exciting milestone for the DayOne Accelerator, with outstanding engagement from both interviewed startups and committee members. The jury was impressed by the breadth of innovation pitched by the 36 ventures to propel Pharma R&D, ranging from AI-aided drug discovery to health tech solutions enabling clinical development for the Pharma industry. There was a shared enthusiasm among everyone involved to be part of and actively contribute to the DayOne ecosystem. We look forward to reconnecting at the Kick-off Bootcamp and continuing this journey together.”
The official announcement of the new cohort will be published in the second half of August.
